Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Toward non-factor therapy in hemophilia: an antithrombin insensitive Gla-domainless factor Xa as tissue factor pathway inhibitor bait

Res Pract Thromb Haemost. 2023-08; 
Marie-Claire Dagher, Atanur Ersayin, Landry Seyve, Mathieu Castellan, Cyril Moreau, Luc Choisnard, Nicole Thielens, Raphaël Marlu, Benoît Polack, Aline Thomas
Products/Services Used Details Operation
Combinatorial DNA Libraries … The cDNA sequences (Genscript) were optimized for … S2 cells were transfected using Freestyle Max Reagent (Life … This was rather puzzling until we discovered that the R150F FXa … Get A Quote

摘要

unassigned: Gla-domainless factor (F) Xa (GD-FXa) was proposed as a trap to endogenous anticoagulant tissue factor pathway inhibitor (TFPI) to restore thrombin generation in hemophilia. Using computational chemistry and experimental approaches, we previously showed that S195A GD-FXa also binds TFPI and restores coagulation in plasma obtained from person(s) with hemophilia. unassigned: To design a GD-FXa variant with improved anti-TFPI affinity, we performed molecular dynamics simulations and identified suitable sites for mutagenesis. The calculations identified residues R150 and K96 as cold-spots of interaction between GD-FXa and the K2 domain of TFPI. In the three-dimensional model, both residues face toward ... More

关键词

Antithrombin, factor Xa, hemophilia, mutagenesis, tissue factor pathway inhibitor
XML 地图